Li Hong-Xing, Ma Xiao-Ling, Ma Wang-Bin, Jia Tian-Yu, Sun Xiao-Hong, He Xiao-Xia, Zhang Li-Li, Xi Ya-Ming
The First School of Clinical Medicine, Lanzhou University, Lanzhou, China.
Clinical Medical Research Center for Reproductive Diseases of Gansu Province, Lanzhou, China.
Front Immunol. 2025 Jun 18;16:1553527. doi: 10.3389/fimmu.2025.1553527. eCollection 2025.
This study aimed to investigate the role of poly(A) binding protein nuclear 1 (PABPN1) as a potential pan-cancer biomarker for prognosis and immunotherapy.
The original datasets were acquired from TCGA and GEO databases. PABPN1 expression analysis was conducted utilizing the Oncomine, TIMER, GEPIA, and BioGPS databases. Prognostic implications of PABPN1 were assessed through GEPIA, Kaplan-Meier plotter, and the PrognoScan database. Correlations between PABPN1 expression and immune checkpoints (ICP), tumor mutational burden (TMB), microsatellite instability (MSI), and neoantigens in human cancers were examined using the SangerBox database. Additionally, the association between PABPN1 and marker genes of tumor-infiltrated immune cells in urogenital cancers was confirmed. Differential expression of PABPN1 in urogenital cancers with distinct clinical characteristics was assessed using the UALCAN database. Finally, experiments of T24, 5637, HLF and MCF-7 cells were performed to verify the above results.
The expression of PABPN1 tended to be higher in human cancers compared to paired normal tissues. Its expression levels showed strong associations with TMB, MSI, and neoantigens. Additionally, significant correlations existed between PABPN1 expression and tumor immune-infiltrated cells (TILs) in many human cancers, with marker genes of TILs showing significant relationships with PABPN1 expression, particularly in urogenital cancers. The coexpression networks of PABPN1 were predominantly involved in the regulation of immune response, antigen processing, and presentation. After down expression of PABPN1, mRNA expression levels of MRPS15 and GPx (Glutathione peroxidase) decreased significantly in T24, 5637 HLF and MCF-7 cells.
PABPN1 was expected to be an important role element in cancer research, serving as a potential prognostic and immunological pan-cancer biomarker.
本研究旨在探讨多聚腺苷酸结合蛋白核1（PABPN1）作为一种潜在的泛癌预后和免疫治疗生物标志物的作用。
原始数据集来自TCGA和GEO数据库。利用Oncomine、TIMER、GEPIA和BioGPS数据库进行PABPN1表达分析。通过GEPIA、Kaplan-Meier绘图仪和PrognoScan数据库评估PABPN1的预后意义。使用SangerBox数据库检测PABPN1表达与人类癌症中免疫检查点（ICP）、肿瘤突变负荷（TMB）、微卫星不稳定性（MSI）和新抗原之间的相关性。此外，还证实了PABPN1与泌尿生殖系统癌症中肿瘤浸润免疫细胞标记基因之间的关联。使用UALCAN数据库评估PABPN1在具有不同临床特征的泌尿生殖系统癌症中的差异表达。最后，对T24、5637、HLF和MCF-7细胞进行实验以验证上述结果。
与配对的正常组织相比，PABPN1在人类癌症中的表达往往更高。其表达水平与TMB、MSI和新抗原密切相关。此外，在许多人类癌症中，PABPN1表达与肿瘤免疫浸润细胞（TILs）之间存在显著相关性，TILs的标记基因与PABPN1表达存在显著关系，尤其是在泌尿生殖系统癌症中。PABPN1的共表达网络主要参与免疫反应、抗原加工和呈递的调节。在T24、5637、HLF和MCF-7细胞中，PABPN1表达下调后，MRPS15和谷胱甘肽过氧化物酶（GPx）的mRNA表达水平显著降低。
PABPN1有望成为癌症研究中的重要角色元素，作为一种潜在的泛癌预后和免疫生物标志物。
Zotero 插件
